Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortiumChijioke Nze, Narendranath Epperla, Allison M. Bock et al.|Blood|2025Cited by 0
Outcomes of CD20 Bispecific Antibodies after CD19 CAR T-cell Therapy in mantle cell lymphoma: A Multicenter Analysis from the Collaborative U.S. Bispecific Consortium (CUBIC)Ajay Major, Andrew Jallouk, Lorenzo Falchi et al.|Transplantation and Cellular Therapy|2026Cited by 0
Performance Status Outperforms Comorbidities As Predictor of Survival after Bsabs for Large B cell LymphomaGeoffrey Shouse, Ayushi Chauhan, Jomel Meeko Manzano et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outcomes of Bispecific Antibody Treatment of Double Hit Lymphoma, a Real-World Evidence (RWE) StudyGeoffrey Shouse, Gulrayz Ahmed, Sairah Ahmed et al.|Transplantation and Cellular Therapy|2026Cited by 0
Outpatient Versus Inpatient Management of Grade 1 Cytokine Release Syndrome in Follicular Lymphoma Patients Receiving Bispecific Antibodies: A Cubic StudyLynnette Henshaw, Jennifer L. Crombie, Sairah Ahmed et al.|Transplantation and Cellular Therapy|2026Cited by 0